We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Bionanomatrix Awarded $397,750 NIH Grant


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bionanomatrix Awarded $397,750 NIH Grant "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

BioNanomatrix LLC has announced receipt of a grant from the National Human Genome Research Institute of the U.S. National Institutes of Health (NIH). 

The two-year $397,750 Small Business Investment Research (SBIR) grant was awarded under the NIH BioEngineering Nanotechnology Initiative.

"We are delighted that the NIH has again recognized the potential of our revolutionary whole genome analysis technology by awarding us this second major grant explicitly intended to support the development and commercialization of our integrated nanofluidics platform," said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix.

"This support will enable us to accelerate development of our platform, which we believe represents a breakthrough in genomic analysis capabilities with broad utility and large commercial potential."

BioNanomatrix is developing integrated systems that enable nanoscale single molecule identification and analysis of the entire genome, delivering single molecule sensitivity with haplotyping capability in a parallel format. 

"The nanochannel array technology we are developing with this funding is designed to permit direct visualization and analysis of multi-megabase fragments of DNA at the single molecule level with high feature resolution, allowing researchers to visualize mutations, haplotypes, epigenetic features and even DNA-protein binding events," said Han Cao, Ph.D., chief scientific officer of BioNanomatrix and the principal investigator on this grant. 

"We believe our technology represents a major advance beyond what is available today, and we are pleased that this new grant will help speed its development."

Advertisement